These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35305260)

  • 21. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib.
    Kristensen LE; Strober B; Poddubnyy D; Leung YY; Jo H; Kwok K; Vranic I; Fleishaker DL; Fallon L; Yndestad A; Gladman DD
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X221149965. PubMed ID: 36777695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies.
    Orbai AM; Husni ME; Gladman DD; Leung YY; Siebert S; Tillett W; Vis M; Chambenoit O; Meng X; Mease PJ
    Rheumatol Ther; 2021 Sep; 8(3):1223-1240. PubMed ID: 34218429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
    McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
    Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis.
    Pournara E; Kormaksson M; Nash P; Ritchlin CT; Kirkham BW; Ligozio G; Pricop L; Ogdie A; Coates LC; Schett G; McInnes IB
    RMD Open; 2021 Nov; 7(3):. PubMed ID: 34795065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative.
    Colombo GL; Di Matteo S; Martinotti C; Jugl SM; Gunda P; Naclerio M; Bruno GM
    Clinicoecon Outcomes Res; 2018; 10():477-491. PubMed ID: 30214261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials.
    Feldman SR; Gomez B; Meng X; Germino R
    J Dermatolog Treat; 2021 Nov; 32(7):709-715. PubMed ID: 31873050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutrophil function following treatment of psoriatic arthritis patients with secukinumab: altered cytokine signalling but no impairment of host defence.
    Cross AL; Hawkes J; Frankland H; Mediana A; Wright HL; Goodson NJ; Edwards SW; Moots RJ
    Rheumatology (Oxford); 2023 Sep; 62(9):3025-3034. PubMed ID: 36617171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry.
    Moreno-Ramos MJ; Sanchez-Piedra C; Martínez-González O; Rodríguez-Lozano C; Pérez-Garcia C; Freire M; Campos C; Cáliz-Caliz R; Calvo J; Blanco-Madrigal JM; Pérez-Gómez A; Moreno-Martínez MJ; Linares L; Sánchez-Alonso F; Sastré C; Castrejón I
    Rheumatol Ther; 2022 Aug; 9(4):1031-1047. PubMed ID: 35467242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks.
    von Stebut E; Reich K; Thaçi D; Koenig W; Pinter A; Körber A; Rassaf T; Waisman A; Mani V; Yates D; Frueh J; Sieder C; Melzer N; Mehta NN; Gori T
    J Invest Dermatol; 2019 May; 139(5):1054-1062. PubMed ID: 30508547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis.
    Pinter A; Gerdes S; Papavassilis C; Reinhardt M
    J Dermatolog Treat; 2020 Dec; 31(8):769-775. PubMed ID: 31287332
    [No Abstract]   [Full Text] [Related]  

  • 31. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
    Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
    Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continued treatment with secukinumab is associated with high retention or regain of response.
    Augustin M; Thaci D; Eyerich K; Pinter A; Radtke M; Lauffer F; Mrowietz U; Gerdes S; Pariser D; Lebwohl M; Sieder C; Melzer N; Reich K
    Br J Dermatol; 2020 Jan; 182(1):67-75. PubMed ID: 30972746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence.
    Braun J; Kiltz U; Bühring B; Baraliakos X
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211041854. PubMed ID: 34471428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years.
    Aparicio M; Guillén-Astete CA; López-Medina C; Sastre C; Rodríguez Martínez FJ
    Rheumatol Ther; 2022 Feb; 9(1):73-94. PubMed ID: 34837630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?
    Rosine N; Miceli-Richard C
    Front Immunol; 2020; 11():553742. PubMed ID: 33488572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison.
    Mease P; Choy E; Nash P; Kalyvas C; Hunger M; Pricop L; Gandhi KK; Jugl SM; Thom H
    Eur J Rheumatol; 2019 Jul; 6(3):113-121. PubMed ID: 31364979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ;
    N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA; Weinberg MA; Morris A; Reich K
    Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study.
    Nash P; Mease PJ; Kirkham B; Singhal A; Quebe-Fehling E; Pricop L; Gaillez C
    Clin Exp Rheumatol; 2022 May; 40(5):952-959. PubMed ID: 34494957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.